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Abstract
Purpose It has been argued that generic health-related
quality of life measures are not sensitive to certain disease-
specific improvements; condition-specific preference-based
measures may offer a better alternative. This paper assesses
the validity, responsiveness and sensitivity of a cancer-
specific preference-based measure, the EORTC-8D, rela-
tive to the EQ-5D-3L.
Methods A longitudinal prospective population-based
cancer genomic cohort, Cancer 2015, was utilised in the
analysis. EQ-5D-3L and the EORTC QLQ-C30 (which
gives EORTC-8D values) were asked at baseline (diagno-
sis) and at various follow-up points (3 months, 6 months,
12 months). Baseline values were assessed for convergent
validity, ceiling effects, agreement and sensitivity. Quality-
adjusted life-years (QALYs) were estimated and similarly
assessed. Multivariate regression analyses were employed
to understand the determinants of the difference in QALYs.
Results Complete case analysis of 1678 patients found that
the EQ-5D-3L values at baseline were significantly lower
than the EORTC-8D values (0.748 vs 0.829, p\ 0.001).
While the correlation between the instruments was high,
agreement between the instruments was poor. The baseline
health state values using both instruments were found to be
sensitive to a number of patient and disease characteristics,
and discrimination between disease states was found to be
similar. Mean generic QALYs (estimated using the EQ-
5D-3L) were significantly lower than condition-specific
QALYs (estimated using the EORTC-8D) (0.860 vs 0.909,
p\ 0.001). The discriminatory power of both QALYs was
similar.
Conclusions When comparing a generic and condition-
specific preference-based instrument, divergences are appar-
ent in both baseline health state values and in the estimated
QALYs over time for cancer patients. The variability in sen-
sitivity between the baseline values and the QALY estima-
tionsmeans researchers and decisionmakers are advised to be
cautious if using the instruments interchangeably.
Keywords Cancer  Condition-specific non-preference-
based measures  Generic preference-based measures 
Quality of life
Introduction
Cost-utility analyses (CUA) require preference-based
measures (PBMs) of outcome. Traditionally PBMs, so-
called multi-attribute utility instruments (MAUIs), have
been generic. The mostly commonly employed generic
PBM is the EQ-5D [1], a measure which the National
Institute for Health and Care Excellence (NICE) actively
encourages [2]. While the use of the same measure across a
range of diseases and conditions increases comparability
(what NICE refers to as a need for consistency) when
informing decisions, there have been criticisms that these
generic measures are not sensitive to certain disease-
specific characteristics [3–5]. This is not withstanding the
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fact that such PBMs have been found to be sensitive to
health issues that the instrument does not explicitly ask
about. For example, the EQ-5D has been found to be
sensitive to a range of clinical features in patients with
Parkinson’s disease including hallucinations [6]. Sensitiv-
ity is therefore a grey area. While using PBMs in some
diseases may mean that important clinical and patient
quality of life changes are missed entirely, in other disease
areas it may be that effects are found, but the magnitude of
these is underestimated. That is, it is not a simple question
of whether PBMs are sensitive, but whether they are sen-
sitive enough?
There are a number of ways in which health economists
can introduce disease-specific sensitivity to the assessment
of outcomes in a CUA [7]. Often they utilise mapping
algorithms which estimate the relationship between a
condition-specific non-preference-based measure and a
generic PBM [8, 9]. A more resource intensive alternative
is to elicit preferences from patients (or the general public)
for condition-specific vignettes describing a health state,
that is to use preference elicitation techniques like time
trade-off, standard gamble or a discrete choice experiment
within the study population [10, 11]. A third alternative is
the use of bolt-ons to existing generic instruments, like
adding vision impairment or hearing impairment to the EQ-
5D [12]. Bolt-ons are thought to improve a generic
instrument’s content validity for a particular condition, but
also retain a core instrument that is comparable across
conditions. A further option which is growing in popularity
is to develop condition-specific preference-based measures
(CSPBMs). CSPBMs can be developed from first princi-
ples (determine dimensions that are important to a
patient/sufferer, design the instrument, undertake a valua-
tion study and produce a set of tariffs) [13], or one could
modify (in many instances this means reduce) an existing
non-preference-based measure and undertake a valuation
study [14]. As these non-preference-based measures have
already been developed for the condition, arguably they
have already been assessed for validity and sensitivity. An
additional benefit of using existing non-preference-based
measures is that clinicians can get information on quality of
life and disease dimensions of interest to them, while
health economists are able to estimate health state values
for use in a CUA without the need to administer an addi-
tional outcome measure.
Despite the apparent benefits of CSPBMs, their use is
limited. If CSPBMs are to be more widely adopted, then
evidence of their performance is required. This does not
negate that many health technology appraisal (HTA)
agencies have an explicit preference for generic instru-
ments, so it may be that even in the face of compelling
evidence of the benefits of CSPBMs implementation will
be restrained. Leaving this debate aside (interested readers
are referred to Versteegh et al. [5] and Brazier and Tsu-
chiya [15]), this paper—using oncology as a case study—
seeks to assess the validity, responsiveness and sensitivity
of a cancer-specific preference-based measure, the
EORTC-8D, relative to a generic PBM, the EQ-5D-3L.
Methods
Data
Cancer 2015 is a large-scale prospective longitudinal
population-based molecular cohort study [16]. It enrols
newly diagnosed/treatment naı¨ve cancer patients irrespec-
tive of the tumour site (except leukaemia) and at all stages
of disease. Recruitment is staged, and phase 1 (2011–2014)
targeted the enrolment of 1000 patients from five hospitals
in Victoria, Australia. It aims to test and implement a new
model of cancer diagnosis and treatment with a specific
focus on integrating molecular pathology into routine
cancer diagnosis [17], whereby all tumours are genotyped
and actionable mutations identified so to inform cancer
diagnosis, prognosis and treatment at an individual level.
The new model is one where personalised treatment plans,
specifically precision medicines guided by genomic testing,
would be offered to patients.
Patients consent to have their tumour biopsy and blood
screened using next-generation sequencing (NGS) [18]. A
baseline questionnaire collects information on patient
socio-demographics and patient and familial history.
Clinical records including pathology results are drawn
upon to gather information on tumour site and stage and
treatment intentions (including changing intentions over
time). Patients are also asked to complete three patient-
reported outcome measures (PROMs); see ‘‘Instruments’’
section for further details. PROMs are repeated at 6- and
12-month follow-up (for those with advanced disease the
first follow-up point was at 3 months).
Instruments
The European Organization for Research and Treatment of
Cancer Quality of Life Questionnaire C30 (EORTC QLQ-
C30) is a non-preference-based health-related quality of
life (HRQoL) measure which is frequently employed in
cancer clinical trials. It is one of a suite of EORTC
instruments and the C30 is regarded as a ‘generic’ cancer
measure (e.g. EORTC QLQ-BR23 is specific to breast
cancer, while EORTC QLQ-MY20 is for myeloma) [19]. It
includes 30 questions which feed into nine multi-item
scales: five functional scales (physical, role, cognitive,
emotional and social functioning); three symptom scales
(fatigue, pain, and nausea and vomiting); and a global
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health status/quality of life scale. Six single-item scales
mainly for symptoms are also included (dyspnoea, insom-
nia, appetite loss, constipation, diarrhoea and financial
difficulties). Cancer 2015 included version 3.0, the most
recent version, which is recommended by the EORTC
Quality of Life Group. The instrument is scored so that it
provides summary scores (between 0 and 100) for a
patient’s functioning, symptoms and global quality of life,
where a higher score represents a higher (‘better’) level of
functioning or quality of life or a higher (‘worse’) level of
symptoms.
The EORTC-8D has eight dimensions (physical func-
tioning, role functioning, pain, emotional functioning,
social functioning, nausea, fatigue and sleep disturbance,
and constipation and diarrhoea) each with 4 levels except
physical functioning which has 5 levels. The instrument
was derived using Rasch and factor analysis from the
EORTC QLQ-C30 [20] with the EORTC-8D drawing on
10 questions from a possible 30. There are 81,920 unique
health states in the EORTC-8D which were valued using
a time trade-off approach in a sample of the general
population from the north of England. The resulting val-
ues range from 0.292 to 1.00, on the full health–dead 1–0
scale.
The EQ-5D-3L (previous known as the EQ-5D) has five
dimensions (mobility, self-care, usual activities, pain/dis-
comfort and anxiety/depression) each with three levels
such that there are 243 health states [21]. The EQ-5D-3L
was also valued using a time trade-off approach in the UK.
Other country valuations exist, some of which use other
valuation techniques (including a discrete choice experi-
ment (DCE) in Australia [22]); however, this analysis
ignores any cross-country differences, and undertakes the
comparison using UK tariffs employing the UK tariff
(MVH-A1 algorithm) for the EQ-5D-3L [23]. The scoring
range for the EQ-5D-3L in the UK is from -0.594 to 1.00,
i.e. it includes states that are worse than dead (\0).
Cancer 2015 also included the EORTC-8D as an
instrument in its own right (i.e. both the 30-item EORTC
QLQ-C30 and the 10-item EORTC-8D were administered
meaning that 10 items were duplicated in the question-
naire), in contrast to deriving EORTC-8D values indirectly
from EORTC QLQ-C30 responses. Although the EORTC-
8D has not been validated (e.g. psychometrically assessed)
as a standalone instrument, it was deemed interesting to
compare the responses of the standalone EORTC-8D with
the derived EORTC-8D given that the standalone instru-
ment is shorter (10 vs 30 questions). Our analysis ignores
the responses to the standalone instrument, however, and
only utilises the derived responses as they were found to be
highly correlated (r = 0.93) and the standalone EORTC-
8D instrument, despite being shorter, had more missing
responses (which was possibly due to an ordering effect in
the questionnaire because the standalone instrument was
included after the C30). Note that phase 2 of Cancer 2015
does not include the EORTC-8D as a standalone
instrument.
Analysis
Using the baseline health state values, we assessed the
normalities of the distribution of each instrument using
both the Shapiro–Wilk W test and the Shapiro–Francia W
test. Skewness and kurtosis were also assessed.
We then assessed the correlation both within dimensions
(using Spearman’s rank) and the health state values as a
whole (using Pearson’s R). We used this correlation matrix
analysis to consider convergent validity (i.e. the degree to
which an instrument/dimension correlates with another
instrument/dimension measuring the same concept) [24].
We expect there to be convergent validity in the items
which are similar, e.g. those measuring physical dimen-
sions of health and those measuring psychological dimen-
sions. Strength of correlation was based on the following
thresholds: r = 0–0.2 (very weak), r = 0.2–0.4 (weak),
r = 0.4–0.7 (moderate), r = 0.7–0.9 (strong), r = 0.9–1.0
(very strong) [25]. It is important to note that the EQ-5D
does not claim to perform measurement within its dimen-
sions (i.e. it does not measure mobility), but instead pro-
vides a simple classification system; however, correlations
within dimensions are commonly undertaken in assess-
ments of validity [26, 27]. We additionally explored ceiling
effects in each instrument by considering the relationship
between item dimensions in one instrument and full health
in the other instrument as measured by a health state value
of 1, e.g. EORTC-8D item responses when the EQ-5D-3L
is one and vice versa.
Agreement between the instruments was examined
using a Bland–Altman plot [28]. This plotted the difference
between EORTC-8D and EQ-5D-3L values against the
mean of the values for each individual. The mean differ-
ence provides the estimate of bias while the limits of
agreement, LOA (based on a ±1.96 9 SDdifference inter-
val), provide an estimate of the influence of random vari-
ation. If there was good agreement between the EORTC-
8D and the EQ-5D-3L, then only 5% of points would lie
outside of the LOA. Agreement was further assessed by
estimating the intra-class correlation coefficient (ICC) [29]
(two way mixed effects with absolute agreement). Strength
of agreement was based on the following thresholds:
ICC = 0–0.2 (poor), ICC = 0.2–0.4 (fair), ICC = 0.4–0.6
(moderate), ICC = 0.6–0.8 (strong) and ICC[ 0.8 (almost
perfect) [29, 30].
To understand the construct validity of each measure,
that is whether the instrument is sensitive (or indeed more
sensitive) to different covariates [24], we compared mean
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health state values using paired t tests and ANOVAs where
appropriate, and estimated the standardised effect size
(difference in means divided by the standard deviation).
The covariates included age, gender, site of recruitment,
insurance status, smoking status, performance/functioning
status (measured using the Eastern Oncology Cooperative
Group (ECOG) performance status scale) at baseline and
over time, initial treatment intention (as an indicator for
severity: none, curative, palliative), planned initial follow-
up point (again as an indicator for severity), status at fol-
low-up (dead or alive), site of tumour and staging of the
disease. We hypothesised that the EORTC-8D would have
a greater ability to discriminate between the disease char-
acteristics (functioning, severity, stage) than the EQ-5D-
3L. We additionally hypothesised that for the patient-level
characteristics (age, gender, insurance status, etc.) both
instruments should have similar levels of discriminatory
power as they are unrelated to condition.
QALYs were estimated using the area under the curve
method. The average time of follow-up was 434 days.
Those who died were given a health state value of zero at
their date of death and included in the QALY calculation.
Correlation between the generic QALYs and condition-
specific QALYs was assessed using Pearson’s R correla-
tion coefficient. The sensitivity of the QALY estimates to
various covariates (as described above) was also explored
in bivariate analyses in order to further assess construct
validity. As above, we hypothesise that there will be more
discrimination with the condition-specific QALYs than
with the generic QALYs for the covariates which reflect
disease characteristics, but they will have equal discrimi-
natory power for the patient-level characteristics. Regres-
sion analysis was employed to further examine the extent
to which the difference in QALYs (condition-specific
minus generic QALYs) was influenced by baseline patient
demographics, disease characteristics, indicators of sever-
ity, change in patient’s performance/functioning (ECOG)
status overtime and the difference in baseline health state
values. A linear model was imposed and the regression was
multivariate with all variables included at the same time.
All statistical analyses were undertaken in STATA MP
version 13.0.
Results
Cancer 2015 recruited its first patient in November 2011,
and as of February 2015 there were 1829 patients enrolled
in the cohort; however, not all patients have complete
PROMs data. We have baseline EQ-5D-3L values for 1715
patients and EORTC-8D values for 1689 patients, and the
complete case sample (where there is a baseline value for
both instruments) is 1678. We are able to estimate generic
and condition-specific QALYs for 1157 patients. Note that
269 patients (nearly 15% of those recruited) have died.
Table 1 presents the descriptive statistics for the sample
at baseline. The sample is elderly (mean age 62), the
majority are male (54%), and a large number have other
co-morbidities as measured by the Charlson Comorbidity
Index (mostly diabetes and arthritis) [31]. The cohort
purposely included a private hospital in the sample (in
order to make treatment comparisons at a later date, and
also because Australia has a two-tiered health care system);
this hospital contributed 19% of the patients, but 43% of
the total sample have insurance cover for hospitals. The
hospital insurance variable can be considered to be
reflective of income, as at a certain income threshold pri-
vate health insurance is incentivised (i.e. an additional tax
is imposed on high income earners who do not have
insurance).
In terms of disease, breast cancer and prostate cancer
contribute the most patients (20% and 15%, respectively)
to the cohort, but there is representation across the spec-
trum of tumour sites. All stages of cancer (staged via the
staging method appropriate to the tumour site) are repre-
sented, and the majority of patients are noted to have
curative treatment intentions at enrolment (82%), although
some patients have palliative treatment intentions. The
large majority of patients (67%) have an ECOG perfor-
mance status which aligns with normal activity [32].
Baseline values
The EORTC QLQ-C30 summary measures are presented in
Table 2; the mean functioning score was 79, mean symp-
tom score was 19, and the mean global health score was 69.
The mean EQ-5D-3L health state value was 0.748, while
the mean health state value for the EORTC-8D was 0.829.
The range of health state values is shown in Fig. 1 which
plots the histograms for the baseline values for each
instrument. The data are skewed and non-normal, and this
is further supported in formal statistical tests (EQ-5D-3L
Shapiro–Wilk test z = 11.8, p\ 0.001; EORTC-8D Sha-
piro–Wilk test z = 10.1, p\ 0.001; EQ-5D-3L Shapiro–
Francia test z = 10.9, p\ 0.001; EORTC-8D Shapiro–
Francia test z = 9.5, p\ 0.001).
There is considerable variability across dimension
responses in both instruments; see ‘‘Appendix’’. The use of
the highest level (no problems) in theEQ-5D-3L ranged from
91.6% of responses for usual activities to 48.3% of responses
for pain/discomfort. For the EORTC-8D, the use of the
highest level ranges from 77.8% of responses for nausea and
30.9% of responses for fatigue and sleep disturbance.
The convergent validity of the instruments is assessed
by considering the correlations across the dimensions and
the health state values. Table 3 shows that correlations
1166 Qual Life Res (2017) 26:1163–1176
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Table 1 Baseline sample
descriptive statistics
Mean (range) or percentage N
Age at consent 61.7 (18, 92) 1678
Charlson Comorbidity Index 2.24 (0, 14) 1510
Gender
Female 45.8% 768
Male 54.2% 909
Recruiting hospital
Public 81.2% 1362
Private 18.8% 316
Hospital insurance cover
Yes 42.5% 697
No 57.5% 943
Smoking status
Current smoker 14.5% 235
Ex-smoker 46.7% 756
Never smoked 38.8% 628
Place of residence
Major city 46.4% 776
Inner regional 47.0% 787
Outer regional 6.6% 111
Tumour site
Prostate 14.9% 249
Breast 19.8% 332
Head and neck 13.2% 221
Colorectal 10.8% 180
Lung 10.3% 172
Bone and soft tissue 3.1% 52
Cervical 2.7% 45
Cancer unknown primary 2.7% 45
Renal 3.5% 58
Oesophagogastric 4.0% 67
Other (includes 12 known sites) 15.2% 254
Stagea
Stage 0 0.9% 15
Stage 1 20.4% 343
Stage 2 23.5% 394
Stage 3 17.8% 298
Stage 4 16.8% 282
Other 6.2% 104
Stage not available 14.4% 242
Treatment intentions
No treatment 1.5% 23
Curative 82.2% 1262
Palliative 16.3% 251
ECOGb score
Normal activity 66.6% 1086
Limited in normal activity 23.4% 381
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between the dimensions of the EQ-5D-3L and the EORTC-
8D are mostly moderate, particular in the dimensions
which appear to be assessing similar constructs, e.g.
physical functioning (EORTC-8D) and mobility (EQ-5D-
3L), pain (EORTC-8D) and pain/discomfort (EQ-5D-3L),
emotional functioning (EORTC-8D) and anxiety/depres-
sion (EQ-5D-3L). The correlation between the baseline
health state values is 0.755, considered to be strong [25].
The correlations between the baseline health state values
and the baseline EORTC QLQ-C30 summary scores are
strong/very strong, ranging from 0.730 to 0.917, except for
the correlation between the EQ-5D-3L health state value
and the global quality of life summary score which is 0.651
(moderate).
Table 1 continued
Mean (range) or percentage N
Self-care capable but not working 7.4% 120
Limited self-care 2.5% 40
No self-care 0.2% 3
a Stage 0 ‘in situ’ cancer, Stage 1 localised cancer, Stage 2 regional spread in the general region it first
began including nearest lymph nodes, Stage 3 regional spread and more extensive lymph node involvement,
Stage 4 distant spread, and Other that could not be classified into any other stage
b ECOG Eastern Oncology Cooperative Group performance status scale
Note that the samples in each category do not always sum to 1678 as there are missing data
Table 2 Descriptive statistics
for health status
Mean SD Min Max N
EQ-5D-3L at baseline 0.748 0.263 -0.594 1.000 1678
EORTC-8D at baseline 0.829 0.147 0.292 1.000 1678
EORTC QLQ-C30 functioning
score at baseline
79.20 18.85 8.89 100 1656
EORTC QLQ-C30 symptom score at
baseline
19.19 17.18 0 89.74 1655
EORTC QLQ-C30 global health
score at baseline
69.00 23.37 0 100 1674
QALYs (from EQ-5D) 0.860 0.018 -0.108 3.138 1157
QALYs (from EORTC-8D) 0.909 0.018 0.001 3.078 1157
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In the assessment of ceiling effects, Tables 4 and 5 show
good content validity; when one instrument records a value
of full health, this corresponds with the higher levels in
each dimension in the other instrument. An exception to
this is the fatigue and sleep disturbance dimension in the
EORTC-8D; 40% of the responses are not at level 1 when
their EQ-5D profiles suggest they are in full health. This
suggests that the generic PBM, in this context, would fail to
pick up impairments in fatigue and sleep disturbance.
The ICC is 0.595 which suggests the agreement between
the measures is moderate. The Bland–Altman plot in Fig. 2
suggests that there are small mean differences between the
two instruments at baseline, but relatively wide limits of
agreement. 6.97% of the data points are found to lie outside
of the LOA suggesting poor agreement between the two
measures, and this is particularly the case for the lower
values of HRQoL.
An analysis of the sensitivity of each instrument to var-
ious subgroups including patient and disease characteristics
(see Table 6, columns 1–4) finds that both the EQ-5D-3L
and the EORTC-8D are sensitive to gender (females have
lower baseline health state values), admission to hospital
(public patients have lower health state values), smoking
status (smokers, including ex-smokers, have lower health
state values), stage of disease (metastatic cancer patients
have lower health state values), hospital insurance (those
without insurance have lower health state values), expected
future follow-up (those with plans for follow-up at three
months—i.e. more advanced disease—have lower baseline
health state values) and ECOG score (those with worse
scores have lower health state values). There is also varia-
tion in cancer site, and both instruments find that prostate
cancer patients have the highest baseline health state values,
while patients with lung cancer and cancer of the unknown
primary (CUP) have the lowest baseline health state values.
Although both instruments identify statistically significant
differences within the covariates, it is notable that the
variation in values is greater for the EQ-5D-3L. However,
the standard deviation for the EORTC-8D is smaller, such
Table 3 Correlations between health state dimensions at baseline
EORTC-8D EQ-5D-3L
Mobility Self-care Usual activities Pain/discomfort Anxiety/depression
Physical functioning 0.599 0.349 0.537 0.436 0.213
Role functioning 0.388 0.352 0.643 0.441 0.243
Pain 0.416 0.289 0.549 0.622 0.261
Emotional functioning 0.171 0.137 0.258 0.265 0.634
Social functioning 0.354 0.341 0.586 0.410 0.314
Fatigue and sleep disturbance 0.331 0.278 0.490 0.439 0.340
Nausea 0.242 0.215 0.379 0.334 0.245
Constipation/diarrhoea 0.277 0.237 0.361 0.295 0.191
All correlations are significant at the p\ 0.001 level
Table 4 EORTC-8D responses
when EQ-5D-3L = 1
(percentages)
Level 1 Level 2 Level 3 Level 4 Level 5
Physical functioning 79.88 17.48 2.44 0.20 0.00
Role functioning 88.01 9.76 1.42 0.81 n/a
Pain 93.09 6.50 0.20 0.20 n/a
Emotional functioning 86.99 12.60 0.41 0.00 n/a
Social functioning 83.94 14.02 1.63 0.41 n/a
Fatigue and sleep disturbance 60.98 34.35 4.27 0.41 n/a
Nausea 94.72 5.08 0.20 0.00 n/a
Constipation/diarrhoea 80.69 16.46 2.03 0.81 n/a
Table 5 EQ-5D-3L responses when EORTC-8D = 1 (percentages)
Level 1 Level 2 Level 3
Mobility 98.62 1.38 0.00
Self-care 100.00 0.00 0.00
Usual activities 98.17 1.36 0.46
Pain/discomfort 91.28 8.72 0.00
Anxiety/depression 92.66 6.88 0.46
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that the estimated effect sizes (not shown) are larger for the
EORTC-8D, although the differences in effect sizes
between the EQ-5D-3L and the EORTC-8D are not sig-
nificant. These findings imply that our initial hypothesis that
the EORTC-8D would have greater discriminatory power
with respect to the disease characteristics (functioning,
severity, stage) is not refuted.
QALYs
The estimated mean QALYs when using the EQ-5D-3L is
0.860 (range -0.108 to 3.138); the estimated mean QALYs
when using the EORTC-8D is 0.909 (range 0.001–3.078);
thus, the QALY estimates are higher for the condition-
specific measure and the range is narrower (see Table 2).
The difference while small (0.049) is statistically signifi-
cant (p\ 0.001, paired t test). The generic and condition-
specific QALYs are very strongly correlated (Pearson’s
R = 0.959); see Fig. 3.
The sensitivity of both types of QALYs to variations in the
sample characteristics is presented in Table 6, columns 5–8.
There are many similarities with the relationships that were
found for baseline health state values (columns 1–4), although
some significant relationships are no longer apparent (for
example, there is no difference in QALY estimates in terms of
whether the patient was recruited in a public or private hospi-
tal).Most notable is that genericQALYsand condition-specific
QALYshave a similar ability to discriminate across patient and
disease characteristics, reporting similar effect sizes.
Table 7 presents the results of a multivariate regression
examining the differences in QALY estimates derived
using the condition-specific measure (EORTC-8D) and the
generic instrument (EQ-5D-3L). The average patient con-
dition-specific QALYs are higher than generic QALYs,
and the results in Table 7 suggest that this can be explained
in part by the variation in baseline health state values,
smoking status, changing ECOG status, advanced disease,
death, and having prostate or bone and soft tissue cancer. A
large variation in baseline health state values results in a
greater difference in QALYs gained. In terms of clinically
relevant variables, patients with prostate cancer (and mar-
ginally for those with bone and soft tissue cancer) relative
to breast cancer patients have greater differences in terms
of condition-specific and generic QALYs. Similarly those
who experienced a decline in their ECOG performance
relative to those who did not change performance status
from baseline to their last follow-up point also have larger
differences in QALY estimates, while those identified at
baseline as having advanced disease thus requiring earlier
follow-up and those who died during the course of follow-
up led to smaller differences between the condition-specific
QALY and the generic QALY.
Discussion
The health economics discipline has been debating condi-
tion-specific measures in the literature for a number of
years [3, 5, 33, 34]. Recently there has been a plethora of
condition-specific measures developed [35–39], but their
use in decision-making remains limited [14]. This paper
further informs the debate by testing the validity, respon-
siveness and sensitivity of a CSPBM for cancer. The
EORTC-8D has previously been found to be broadly
comparable to the EQ-5D [40], but that was within the
same dataset that the EORTC-8D was developed from;
thus, wider evaluation is required. This study provides one
of the first external assessments of the instrument in
comparison with EQ-5D-3L (see Hatswell et al. [41] for a
comparison of EORTC-8D to SF-6D).
Descriptive analysis found that the mean health state
value for the EORTC-8Dwas higher than for the EQ-5D-3L.
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Lloyd et al. [42] also found that the EORTC-8D scores were
higher than EQ-5D-5L scores (a newer 5-level version of the
EQ-5D [43]) in a group of men with metastatic castration-
resistant prostate cancer. This may be a function of the
EORTC-8D having a higher ‘floor’, and the lowest possible
health state value is 0.292 compared with the EQ-5D-3L
floor of-0.594. The greater range of values for the EQ-5D-
3Lmay be observed because there is a greater opportunity for
there to be lower values due to the theoretically plausible
wider range of values that are available. Note that in the
provisional EQ-5D-5L tariff for England theminimumvalue
for the worst health state (55555) is -0.281 [44], while in
other countries the worst health state values range from
-0.446 [45] to -0.148 [46]. Further comparative analysis
should be undertaken to consider the effect of the 5-level
version, and note that Lloyd et al. [42] used a crosswalk from
the 3L to the 5L. TheEQ-5D-5L has been included in the next
phase of Cancer 2015 [16].
Our assessment of convergent validity found that the
dimensions and instruments were strongly correlated, while
the analysis of content validity found few ceiling effects.
Despite this, the agreement between the instruments was
poor, with considerable variation in values for those with
lower baseline HRQoL. Similar wide confidence intervals
have been reported by others when comparing alternative
generic MAUIs [47, 48].
The condition-specific QALYs estimated using the
EORTC-8Dwere significantly higher than those derived from
differences in the EQ-5D-3L over time (although the differ-
ence was small). Both the generic and condition-specific
QALYs were found to be similarly sensitive to a number of
patient and disease characteristics. Multivariate regression
analysis of the difference inQALY estimates at a patient level
found variation in baseline health state values had a large
influence on the difference inQALYs gained, such that higher
baseline EORTC-8Dhealth state values relative to EQ-5D-3L
values yield higher condition-specific QALYs compared to
generic QALYs. This is despite the fact that higher baseline
values mean there is less utility space in which to improve,
given that health state values are bounded at 1. However, this
may be driven by greater variation at the lower end of the
health state values which would reaffirm the Bland–Altman
results presented earlier (Fig. 2) where the poor agreement
was driven by the patientswith lower (mean) baselineHRQoL
who also happened to have larger baseline differences.
Previous analysis [40] suggests that the EORTC-8D
produced outcome values that are as valid, responsive and
sensitive as EQ-5D-3L values. Our findings align with this,
and at baseline the EQ-5D-3L and EORTC-8D values have a
similar ability to discriminate between groups. This is also
carried through to the QALY estimation where both generic
and condition-specific QALYs appear equally responsive
and sensitive to disease characteristics. When specifically
considering the difference in QALYs, we find that this is
most sensitive to differences in baseline health state values
which are larger for those with lower HRQoL and in patients
with declining performance and for particular sites. There-
fore, researchers producing QALYs estimates from the
EORTC-8D and decision makers utilising this information
are advised to be cautious if their target group includes such
patients. Caution is also advised if researchers/decision
makers are using the instruments interchangeably (as may be
the case in modelled economic evaluations) as the health
state values differ considerably between instruments.
A limitation of this study is that while the cohort is rich in
information it is not a clinical trial, and therefore, treatment
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Table 6 Differences in baseline health state values and QALYs
EQ-5D-3L baseline
value
EORTC-8D baseline
value
Generic QALYs Condition-specific
QALYs
Mean p value Mean p value Mean p value Mean p value
Male 0.767 0.001 0.847 \0.001 0.889 0.079 0.940 0.059
Female 0.726 0.808 0.824 0.870
Aged\30 years 0.722 0.307 0.792 0.005 0.751 \0.001 0.798 \0.001
Aged 30–50 years 0.724 0.818 0.943 1.003
Aged 50–70 years 0.757 0.840 0.909 0.965
Aged[70 years 0.743 0.814 0.714 0.742
Public hospital recruitment 0.732 \0.001 0.819 \0.001 0.848 0.141 0.902 0.435
Private hospital recruitment 0.818 0.875 0.919 0.940
Hospital insurance—no 0.717 \0.001 0.811 \0.001 0.822 0.006 0.876 0.017
Hospital insurance—yes 0.794 0.855 0.924 0.965
Smoker 0.689 0.001 0.814 0.037 0.775 0.012 0.875 0.013
Ex-smoker 0.752 0.824 0.836 0.867
Never smoked 0.763 0.840 0.930 0.982
ECOG—normal activity 0.824 \0.001 0.878 \0.001 0.996 \0.001 1.037 \0.001
ECOG—limited in normal activity 0.671 0.771 0.715 0.775
ECOG—self-care capable but not working 0.500 0.663 0.433 0.490
ECOG—limited self-care 0.270 0.570 0.439 0.533
ECOG—no self-care 0.190 0.689 0.020 0.030
Change in ECOG—none 0.820 \0.001 0.871 \0.001 1.108 \0.001 1.147 \0.001
Change in ECOG—decline 0.675 0.783 0.495 0.558
Change in ECOG—improvement 0.670 0.772 0.952 1.001
Treatment intent—none 0.726 \0.001 0.818 \0.001 0.426 \0.001 0.601 \0.001
Treatment intent—curative 0.787 0.855 0.977 1.023
Treatment intent—palliative 0.603 0.728 0.467 0.518
Planned six month follow-up 0.762 \0.001 0.838 \0.001 0.934 \0.001 0.988 \0.001
Planned three month follow-up 0.631 0.757 0.420 0.441
Alive at follow-up 0.772 \0.001 0.844 \0.001 1.002 \0.001 1.051 \0.001
Dead at follow-up 0.616 0.748 0.337 0.383
Site—prostate 0.867 \0.001 0.921 \0.001 1.166 \0.001 1.220 \0.001
Site—breast 0.776 0.841 0.894 0.929
Site—head and neck 0.718 0.843 0.910 0.996
Site—colorectal 0.780 0.804 0.845 0.831
Site—lung 0.647 0.758 0.600 0.652
Site—bone and soft tissue 0.665 0.808 0.922 1.040
Site—cervical 0.784 0.855 1.041 1.089
Site—CUP 0.611 0.774 0.472 0.550
Site—renal 0.735 0.813 0.755 0.770
Site—oesophagogastric 0.686 0.789 0.570 0.610
Site—all other 0.724 0.803 0.801 0.856
Stage 0 0.750 \0.001 0.833 \0.001 0.756 \0.001 0.874 \0.001
Stage 1 0.781 0.849 1.056 1.102
Stage 2 0.785 0.851 0.985 1.016
Stage 3 0.784 0.846 0.901 0.947
Stage 4 0.673 0.789 0.697 0.764
Stage—other 0.657 0.782 0.596 0.663
Stage—not staged 0.728 0.813 0.608 0.647
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effects vary.More research is required to compare the generic
PBM and CSPBM in a trial setting. A further future limitation
is that an additional PBM using the EORTC QLQ-C30 is
underdevelopment (QLU-C10D) [49–51]. While the
EORTC-8Dclassification systemwas derived using data from
multiple myeloma patients, the new measure utilises data
Table 7 Regression results
examining the difference in
QALYs
Coefficient p value
Difference in baseline health state value 0.332 \0.001
Female 0.004 0.779
Age (reference\30 years)
Aged 30–50 years 0.035 0.419
Aged 50–70 years 0.034 0.434
Aged[70 years 0.012 0.786
Private hospital recruitment -0.027 0.107
Has hospital insurance 0.003 0.802
Smoking status (reference smoker)
Ex-smoker -0.039 0.011
Never smoked -0.021 0.181
ECOG status (reference normal)
Limited in normal activity 0.027 0.075
Self-care capable but not working 0.013 0.571
Limited self-care -0.023 0.541
Change in ECOG status (reference no change)
Decline in ECOG status 0.055 \0.001
Improvement in ECOG status -0.013 0.527
Treatment intent (reference no treatment plan)
Curative -0.016 0.480
Palliative -0.014 0.582
Planned three month follow-up (e.g. advanced disease) -0.045 0.008
Dead at follow-up -0.066 0.001
Site (reference breast)
Prostate 0.046 0.045
Head and neck 0.038 0.102
Colorectal -0.030 0.169
Lung 0.002 0.920
Bone and soft tissue 0.057 0.051
Cervical 0.013 0.690
CUP -0.015 0.644
Renal 0.014 0.730
Oesophagogastric 0.009 0.762
All other 0.007 0.744
Stage (reference stage 1)
Stage 0 0.059 0.309
Stage 2 -0.028 0.080
Stage 3 -0.003 0.883
Stage 4 0.003 0.870
Stage—other 0.030 0.307
Stage—not staged -0.025 0.252
Constant -0.023 0.711
Adjusted R2 0.154
N 1115
Dependent variable is condition-specific QALYs minus generic QALYs
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frommultiple countries andmultiple types of cancer to derive
its classification system and in addition aims to produce
country-specific preference weights for a range of different
countries including the UK and Australia. Both instruments
draw on the EORTCQLQ-C30 which the EORTCQuality of
Life Group suggests is supplemented by disease-specific
modules (e.g.QLQ-BR23 for breast,QLQ-MY20 formultiple
myeloma). Therefore, it may be that more specificity is
requiredwithoncologyassessments andboth of theseCSPBM
require further supplementation.
There is growing concern with respect to the high cost of
personalised or targeted drugs for cancer treatment
[52, 53]; the greater financial risk means that it is even
more important to accurately measure the outcomes of
treatment to estimate if treatment offers value for money.
Our research suggests that CSPBMs offer both similarities
and differences to generic PBMs, and while this difference
equates to marginally higher QALYs in our cohort, further
research is required to confirm if these higher QALYs offer
a more accurate reflection of HRQoL gains [54].
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